Genentech/Novartis Xolair Approval Could Be Delayed Until Early 2002
Genentech/Novartis Xolair (omalizumab) approval could be pushed back to early 2002 as the companies prepare to submit additional safety data to FDA.
Genentech/Novartis Xolair (omalizumab) approval could be pushed back to early 2002 as the companies prepare to submit additional safety data to FDA.